Lee’s Pharmaceutical Projects Significant Profit Increase for 2024

Lee’s Pharmaceutical Holdings Limited ( (HK:0950) ) just unveiled an announcement.

Lee’s Pharmaceutical Holdings Limited has issued a positive profit alert, anticipating a significant increase in net profit for the year ending December 31, 2024, with expected figures between HK$83 million and HK$106 million, compared to HK$17 million the previous year. This improvement is attributed to robust sales growth from key products, decreased R&D expenses through portfolio optimization, and cost savings from management initiatives, despite challenges such as land use rights provisions and R&D impairment losses.

More about Lee’s Pharmaceutical Holdings Limited

Lee’s Pharmaceutical Holdings Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on the development, production, and sales of pharmaceutical products, with a market focus on drugs included in the National Reimbursement Drug List and those selected in the volume-based procurement program.

YTD Price Performance: -2.11%

Average Trading Volume: 193,281

Technical Sentiment Consensus Rating: Hold

Current Market Cap: HK$818.5M

Learn more about 0950 stock on TipRanks’ Stock Analysis page.